Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2022 Earnings Call Transcript

Janet Hammond : Sure. Yes, the answer is no. The FDA has endorsed and reviewed our Phase 3clinical trial. And I think, as we described, patients are being randomized to drug or placebo on top of what is the available standard of care for the patient where they are. And actually, I think, as Jean Sommadossi mentioned in his remarks, there actually are significant number of people, and actually, particularly unfortunately, in the most vulnerable patient population, people who are unable to take Paxlovid because of drug interactions. And so for patients such as these, our drug is administered on standard of care, which would not include a direct acting antiviral. We do allow patients to have access to direct acting antivirals monoclonal antibodies if those were to be considered to be effective. And patients are allowed to be vaccinated also. But many patients, we believe, will actually not be taking anything other than our drug or placebo because of these circumstances.

Operator: We have another question from Roanna Ruiz of SVB Securities.

Roanna Ruiz: Hey, thanks for taking that extra question. I just want to circle back about the possibility of an EUA for Bemnifosbuvir. Do you have any updated thoughts on that?

Jean Sommadossi: Janet?

Janet Hammond : I’m so sorry. I realized as soon as I finished that I hadn’t gone to your question completely. Yes. So we believe that an emergency use authorization is still possible. I think it’s at the discretion of the Health and Human Services to allow four EUAs even with the passing or the lapsing of the pandemic health emergency. So we believe it will be data driven and depending on what we see as to whether such a thing might be possible. But we believe it is still possible, should we have good results, even at the interim analysis.

Operator: Thank you. That concludes our Q&A segment. I’ll now turn it back over to Atea Pharmaceuticals team for any closing remarks.

A – Jean Sommadossi: Again, thank you all for joining us today.

Operator: And thank you for your participation in today’s conference. This does conclude the program. You may now disconnect.